Keywords: UK, Medicines access, Drug price cuts, NICE, PPRS, GlaxoSmithKline CEO, Cancer drugs, EMIG

GSK boss accuses UK government of blocking new drugs to save money

Article | 27 February 2012

Print This

The chief executive of the UK’s largest pharmaceutical company, GlaxoSmithKline (LSE: GSK) has accused the government of "systematically ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in